- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
* IN BRIEF * 08 May 2019 By * Sarah Crunkhorn * Sarah Crunkhorn The fat mass and obesity-associated gene (_FTO_) has been implicated in metabolic disorders, but precisely how FTO is involved
in metabolic regulation remains unknown. Through a structure-based virtual screen of FDA-approved drugs, Peng et al. identify the Parkinson’s disease treatment, entacapone, as a potent FTO
inhibitor. In mouse models of obesity and diabetes, entacapone reduced body weight and fasting blood glucose levels. Mechanistically, FTO demethylated m6A sites on forkhead box protein O1
mRNA to up-regulate expression, thereby modulating gluconeogenesis and thermogenesis. ACCESS OPTIONS Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value
online-access subscription $29.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Rent or buy this
article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: _Nature Reviews Drug Discovery_
18, 420 (2019) _doi: https://doi.org/10.1038/d41573-019-00082-z_ REFERENCES
